{"id":"gc3110a-trivalent","safety":{"commonSideEffects":[]},"_chembl":null,"_fixedAt":"2026-03-30T13:27:25.264642","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a trivalent formulation, GC3110A likely combines three distinct antigenic components or epitopes to broaden immune coverage. The specific mechanism depends on its target disease, but therapeutic vaccines typically work by activating T-cell and/or B-cell responses to enhance the body's ability to recognize and eliminate disease-associated cells or pathogens.","oneSentence":"GC3110A is a trivalent vaccine designed to stimulate immune responses against multiple targets for therapeutic benefit.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:12:59.137Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"_fixedFields":["pubmed(4)"],"trialDetails":[{"nctId":"NCT02352584","phase":"PHASE3","title":"A Multicenter, Double-blind, Parallel Phase III Study","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2014-10","conditions":"Influenza","enrollment":1299},{"nctId":"NCT02121782","phase":"PHASE1, PHASE2","title":"A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine)","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2014-05","conditions":"Influenza","enrollment":84}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"recentPublications":[{"date":"2021 Jun 16","pmid":"33992436","title":"Safety and immunogenicity of a seasonal quadrivalent influenza vaccine (GC3110A) in healthy participants aged ≥ 65 years.","journal":"Vaccine"},{"date":"2021 Apr 8","pmid":"33736920","title":"Active-controlled phase III study of an egg-cultivated quadrivalent inactivated split-virion influenza vaccine (GC3110A) in healthy Korean children aged 6-35 months.","journal":"Vaccine"},{"date":"2019","pmid":"30396317","title":"Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase Ⅲ randomized clinical trial in adults.","journal":"Human vaccines & immunotherapeutics"},{"date":"2018 Mar 26","pmid":"29573247","title":"Safety and Immunogenicity of an Egg-Cultivated Quadrivalent Inactivated Split-virion Influenza Vaccine (GC3110A) in Healthy Korean Children: a Randomized, Double-blinded, Active-controlled Phase III Study.","journal":"Journal of Korean medical science"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GC3110A"],"phase":"phase_3","status":"active","brandName":"GC3110A(Trivalent)","genericName":"GC3110A(Trivalent)","companyName":"Green Cross Corporation","companyId":"green-cross-corporation","modality":"Biologic","firstApprovalDate":"","aiSummary":"GC3110A(Trivalent) is a small molecule vaccine used to study the safety and tolerability of a trivalent influenza vaccine. It is a supplement that is being investigated as a potential treatment for influenza.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}